CAMK2N1 and ductal breast carcinoma in situ: These 4 markers, plus CAMK2N1, enriched for patients who did not progress to IDC by 3.6-fold using the criteria of 0–1 gene down regulated and CAMK2N1 high (Lower Hazard group) (36% vs 10%, - patients from the Pure DCIS group vs patients with an IDC diagnosis), whereas 3–4 genes down regulated or CAMK2N1 low (Higher Hazard group) enriched for patients that received a diagnosis of IDC by 1.7-Fold (71% vs 42% – patients with an IDC diagnosis vs patients from the Pure DCIS group; Fig. S8).